Site-directed delivery of nitric oxide to cancers

Nitric Oxide - Biology and Chemistry

Volumn 43, Issue , 2014, Pages 8-16

  Sharma, Kavita ^a   Chakrapani, Harinath ^a  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

Diazeniumdiolate; Drug delivery; Enzyme; Glutathione; Prodrug

Indexed keywords

DOXORUBICIN; ESTERASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITROREDUCTASE; NITROSAMINE; PRODRUG; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; CANCER CELL; CANCER CHEMOTHERAPY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG ACTIVATION; DRUG METABOLISM; GENE DIRECTED ENZYME PRODRUG THERAPY; HISTONE PHOSPHORYLATION; HUMAN; INTRACELLULAR SPACE; MAMMAL CELL; MOLECULARLY TARGETED THERAPY; NITRATION; NONHUMAN; REVIEW; DOSE RESPONSE; DRUG DELIVERY SYSTEM; NEOPLASMS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NITRIC OXIDE; PRODRUGS;

EID: 84912520958     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2014.07.005     Document Type: Review

References (110)

1. J.P. Kiss Role of nitric oxide in the regulation of monoaminergic neurotransmission Brain Res. Bull 52 2000 459 466
2. P.B. Massion, O. Feron, C. Dessy, and J.-L. Balligand Nitric oxide and cardiac function: ten years after, and continuing Circ. Res 93 2003 388 398
3. M. Rosselli, R. Keller, and R. Dubey Role of nitric oxide in the biology, physiology and pathophysiology of reproduction Hum. Reprod. Update 4 1998 3 24
4. G.-R. Wang, Y. Zhu, P.V. Halushka, T.M. Lincoln, and M.E. Mendelsohn Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase Proc. Natl. Acad. Sci. U.S.A. 95 1998 4888 4893
5. M. Jones, J. Ganopolsky, A. Labbé, C. Wahl, and S. Prakash Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices Appl. Microbiol. Biotechnol 88 2010 401 407
6. S. Habib, and A. Ali Biochemistry of nitric oxide Indian J. Clin. Biochem 26 2011 3 17
7. J. Muntane, and M.D. la Mata Nitric oxide and cancer World J. Hepatol 2 2010 337 344
8. S.J. Bailey, A. Vanhatalo, P.G. Winyard, and A.M. Jones The nitrate-nitrite-nitric oxide pathway: its role in human exercise physiology Eur. J. Sport Sci 12 2011 309 320
9. S. Korde Choudhari, M. Chaudhary, S. Bagde, A. Gadbail, and V. Joshi Nitric oxide and cancer: a review World J. Surg. Oncol 11 2013 118
10. W. Xu, L.Z. Liu, M. Loizidou, M. Ahmed, and I.G. Charles The role of nitric oxide in cancer Cell Res 12 2002 311 320
11. J.O. Lundberg, E. Weitzberg, and M.T. Gladwin The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics Nat. Rev. Drug Discov 7 2008 156 167
12. E. Weitzberg, M. Hezel, and J.O. Lundberg Nitrate-nitrite-nitric oxide pathway: implications for anesthesiology and intensive care Anesthesiology 113 2010 1460 1475 10.1097/ALN.0b013e3181fcf3cc
13. T.A. Heinrich, R.S. da Silva, K.M. Miranda, C.H. Switzer, D.A. Wink, and J.M. Fukuto Biological nitric oxide signalling: chemistry and terminology Br. J. Pharmacol 169 2013 1417 1429
14. L.A. Ridnour, D.D. Thomas, C. Switzer, W. Flores-Santana, J.S. Isenberg, and S. Ambs Molecular mechanisms for discrete nitric oxide levels in cancer Nitric Oxide 19 2008 73 76
15. P.G. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, and T. Cai Nitric oxide donors: chemical activities and biological applications Chem. Rev 102 2002 1091 1134
16. A.J. Burke, F.J. Sullivan, F.J. Giles, and S.A. Glynn The yin and yang of nitric oxide in cancer progression Carcinogenesis 34 2013 503 512
17. C. Szabó Multiple pathways of peroxynitrite cytotoxicity Toxicol. Lett 140-141 2003 105 112
18. C. Szabo, H. Ischiropoulos, and R. Radi Peroxynitrite: biochemistry, pathophysiology and development of therapeutics Nat. Rev. Drug Discov 6 2007 662 680
19. Y. Kuang, K. Balakrishnan, V. Gandhi, and X. Peng Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs J. Am. Chem. Soc 133 2011 19278 19281
20. E.W. Miller, O. Tulyanthan, E.Y. Isacoff, and C.J. Chang Molecular imaging of hydrogen peroxide produced for cell signaling Nat. Chem. Biol 3 2007 263 267
21. A.E. Maciag, H. Chakrapani, J.E. Saavedra, N.L. Morris, R.J. Holland, and K.M. Kosak The nitric oxide prodrug js-k is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species J. Pharmacol. Exp. Ther 336 2011 313 320
22. C. Riganti, E. Miraglia, D. Viarisio, C. Costamagna, G. Pescarmona, and D. Ghigo Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res 65 2005 516 525
23. K. Chegaev, C. Riganti, L. Lazzarato, B. Rolando, S. Guglielmo, and I. Campia Nitric oxide donor doxorubicins accumulate into doxorubicin-resistant human colon cancer cells inducing cytotoxicity ACS Med. Chem. Lett 2 2011 494 497
24. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med 53 2002 615 627
25. G.J. Zaman, M.J. Flens, M.R. van Leusden, M. de Haas, H.S. Mülder, and J. Lankelma The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump Proc. Natl. Acad. Sci. U.S.A. 91 1994 8822 8826
26. K. Moitra, H. Lou, and M. Dean Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development Clin. Pharmacol. Ther 89 2011 491 502
27. R. Fruttero, M. Crosetti, K. Chegaev, S. Guglielmo, A. Gasco, and F. Berardi Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein J. Med. Chem 53 2010 5467 5475
28. C. Riganti, B. Rolando, J. Kopecka, I. Campia, K. Chegaev, and L. Lazzarato Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance Mol. Pharm 10 2012 161 174
29. J.M. Brown, and W.R. Wilson Exploiting tumour hypoxia in cancer treatment Nat. Rev. Cancer 4 2004 437 447
30. A.M. Shannon, D.J. Bouchier-Hayes, C.M. Condron, and D. Toomey Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies Cancer Treat. Rev 29 2003 297 307
31. R. Sullivan, G.C. Paré, L.J. Frederiksen, G.L. Semenza, and C.H. Graham Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity Mol. Cancer Ther 7 2008 1961 1973
32. L.J. Frederiksen, R. Sullivan, L.R. Maxwell, S.K. Macdonald-Goodfellow, M.A. Adams, and B.M. Bennett Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling Clin. Cancer Res 13 2007 2199 2206
33. B. Bonavida, S. Khineche, S. Huerta-Yepez, and H. Garbán Therapeutic potential of nitric oxide in cancer Drug Resist. Updat 9 2006 157 173
34. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat. Rev. Cancer 11 2011 393 410
35. R.L. Cowen, E.J. Garside, B. Fitzpatrick, M.V. Papadopoulou, and K.J. Williams Gene therapy approaches to enhance bioreductive drug treatment. Brit J. Radiol 81 2008 S45 S56
36. M. De Ridder, D. Verellen, V. Verovski, and G. Storme Hypoxic tumor cell radiosensitization through nitric oxide Nitric Oxide 19 2008 164 169
37. J.B. Mitchell, D.A. Wink, W. DeGraff, J. Gamson, L.K. Keefer, and M.C. Krishna Hypoxic mammalian cell radiosensitization by nitric oxide Cancer Res 53 1993 5845 5848
38. H. Yasuda Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer Nitric Oxide 19 2008 205 216
39. K.L. Talks, H. Turley, K.C. Gatter, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages Am. J. Pathol 157 2000 411 421
40. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 3 2003 721 732
41. K. Sogawa, K. Numayama-Tsuruta, M. Ema, M. Abe, H. Abe, and Y. Fujii-Kuriyama Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia Proc. Natl. Acad. Sci. U.S.A. 95 1998 7368 7373
42. F.H. Agani, M. Puchowicz, J.C. Chavez, P. Pichiule, and J. LaManna Role of nitric oxide in the regulation of HIF-1α expression during hypoxia Am. J. Physiol. Cell Physiol 283 2002 C178 C186
43. S. Huerta, S. Chilka, and B. Bonavida Nitric oxide donors: novel cancer therapeutics (review) Int. J. Oncol 33 2008 909 927
44. P. Sonveaux, B.F. Jordan, B. Gallez, and O. Feron Nitric oxide delivery to cancer: why and how? Eur. J. Cancer 45 2009 1352 1369
45. D. Hirst, and T. Robson Targeting nitric oxide for cancer therapy J. Pharm. Pharmacol 59 2007 3 13
46. H. Chakrapani, M.D. Bartberger, and E.J. Toone C-nitroso donors of nitric oxide J. Org. Chem 74 2009 1450 1453
47. V. McMurtry, J. Saavedra, R. Nieves-Alicea, A. Simeone, L. Keefer, and A. Tari JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells Int. J. Oncol 38 2011 963 971
48. R.S. Nandurdikar, A.E. Maciag, R.J. Holland, Z. Cao, P.J. Shami, and L.M. Anderson Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs Bioorg. Med. Chem. Lett 20 2012 3094 3099
49. P.J. Shami, J.E. Saavedra, C.L. Bonifant, J. Chu, V. Udupi, and S. Malaviya Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo J. Med. Chem 49 2006 4356 4366
50. R.S. Nandurdikar, L.K. Keefer, and J.E. Saavedra Novel protection-deprotection strategies in diazeniumdiolate chemistry: synthesis of V-IPA/NO Chem. Commun 47 2011 6710 6712
51. T.B. Cai, D.N. Lu, M. Landerholm, and P.G. Wang Sialated diazeniumdiolate: a new sialidase-activated nitric oxide donor Org. Lett 6 2004 4203 4205
52. Y. Hou, J. Wang, P.R. Andreana, G. Cantauria, S. Tarasia, and L. Sharp Targeting nitric oxide to cancer cells: cytotoxicity studies of glyco-S-nitrosothiols Bioorg. Med. Chem. Lett 9 1999 2255 2258
53. D. Lu, J. Nadas, G. Zhang, W. Johnson, J.L. Zweier, and A.J. Cardounel 4-Aryl-1,3,2-oxathiazolylium-5-olates as pH-controlled NO-donors: the next generation of S-nitrosothiols J. Am. Chem. Soc 129 2007 5503 5514
54. R.V. Blackburn, S.S. Galoforo, C.M. Berns, N.M. Motwani, P.M. Corry, and Y.J. Lee Differential induction of cell death in human glioma cell lines by sodium nitroprusside Cancer 82 1998 1137 1145
55. C.X. Zhang, and S.J. Lippard New metal complexes as potential therapeutics Curr. Opin. Chem. Biol 7 2003 481 489
56. K. Sumitani, R. Kamijo, and M. Nagumo Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of c-myc and c-myb proto-oncogene expression Anticancer Res 17 1997 865 871
57. Z.-H. Zou, X.-B. Lan, H. Qian, W.-L. Huang, and Y.-M. Li Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents Bioorg. Med. Chem. Lett 21 2011 5934 5938
58. S. Moharram, A. Zhou, L.I. Wiebe, and E.E. Knaus Design and Synthesis of 3′- and 5′-O-(3-Benzenesulfonylfuroxan-4-yl)-2′-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents J. Med. Chem 47 2004 1840 1846
59. G. Aguirre, M. Boiani, H. Cerecetto, M. Fernández, M. González, and E. León Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies Pharmazie 61 2006 54 59
60. J.M. Brown Tumor hypoxia in cancer therapy S. Helmut, B. Bernhard, Method Enzymol vol. 435 2007 Academic Press 295 321
61. K.M. Davies, D.A. Wink, J.E. Saavedra, and L.K. Keefer Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution J. Am. Chem. Soc 123 2001 5473 5481
62. F. Friedlos, W.A. Denny, B.D. Palmer, and C.J. Springer Mustard prodrugs for activation by escherichia coli nitroreductase in gene-directed enzyme prodrug therapy J. Med. Chem 40 1997 1270 1275
63. G. Xu, and H.L. McLeod Strategies for enzyme/prodrug cancer therapy Clin. Cancer Res 7 2001 3314 3324
64. O. Greco, and G.U. Dachs Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives J. Cell. Physiol 187 2001 22 36
65. G. Chung-Faye, D. Palmer, D. Anderson, J. Clark, M. Downes, and J. Baddeley Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase i and pharmacokinetic study of its prodrug, CB1954 Clin. Cancer Res 7 2001 2662 2668
66. J. Fang, T. Sawa, and H. Maeda Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS H. Maeda, A. Kabanov, K. Kataoka, T. Okano, U.S. Springer, Polymer Drugs in the Clinical Stage vol. 519 2003 29 49
67. K. Greish Enhanced Permeability and Retention (EPR) effect for anticancer nanomedicine drug targeting S.R. Grobmyer, B.M. Moudgil, Cancer Nanotechnology vol. 624 2010 Humana Press 25 37
68. J.E. Saavedra, P.J. Shami, L.Y. Wang, K.M. Davies, M.N. Booth, and M.L. Citro Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: in vitro antileukemic activity J. Med. Chem 43 1999 261 269
69. R.C. Strange, P.W. Jones, and A.A. Fryer Glutathione S-transferase: genetics and role in toxicology Toxicol. Lett 112-113 2000 357 363
70. V.J. Findlay, D.M. Townsend, J.E. Saavedra, G.S. Buzard, M.L. Citro, and L.K. Keefer Tumor cell responses to a novel glutathione S-transferase-Activated nitric oxide-releasing prodrug Mol. Pharm 65 2004 1070 1079
71. D.M. Townsend, and K.D. Tew The role of glutathione-S-transferase in anti-cancer drug resistance Oncogene 22 2003 7369 7375
72. W.Z. Yang, A. Begleiter, J.B. Johnston, L.G. Israels, and M.R. Mowat Role of glutathione and glutathione S-transferase in chlorambucil resistance Mol. Pharmacol 41 1992 625 630
73. A.E. Maciag, J.E. Saavedra, and H. Chakrapani The nitric oxide prodrug js-k and its structural analogues as cancer therapeutic agents Anticancer Agents Med. Chem 9 2009 798 803
74. C. Weidensteiner, W. Reichardt, P.J. Shami, J.E. Saavedra, L.K. Keefer, and B. Baumer Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI Nitric Oxide 30 2013 17 25
75. A.-M. Simeone, V. McMurtry, R. Nieves-Alicea, J. Saavedra, L. Keefer, and M. Johnson TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells Breast Cancer Res 10 2008 R44
76. M. Laschak, K.-D. Spindler, A. Schrader, A. Hessenauer, W. Streicher, and M. Schrader JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells BMC Cancer 12 2012 130
77. P.J. Shami, A.E. Maciag, J.K. Eddington, V. Udupi, K.M. Kosak, and J.E. Saavedra JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C) Leuk. Res 33 2009 1525 1529
78. N. Nath, M. Chattopadhyay, L. Pospishil, L.Z. Cieciura, S. Goswami, and R. Kodela JS-K; a nitric oxide-releasing prodrug, modulates β-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism Biochem. Pharmacol 80 2010 1641 1649
79. M.Z. Kaczmarek, R.J. Holland, S.A. Lavanier, J.A. Troxler, V.I. Fesenkova, and C.A. Hanson Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells Leuk. Res 38 2014 377 382
80. V. Kumar, S.Y. Hong, A.E. Maciag, J.E. Saavedra, D.H. Adamson, and R.K. Prud'homme Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles Mol. Pharm 7 2009 291 298
81. H. Chakrapani, T.C. Wilde, M.L. Citro, M.M. Goodblatt, L.K. Keefer, and J.E. Saavedra Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: structural analogues of PABA/NO, an anti-cancer lead compound Bioorg. Med. Chem 16 2008 2657 2664
82. H. Chakrapani, B.M. Showalter, L. Kong, L.K. Keefer, and J.E. Saavedra V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO Org. Lett 9 2007 3409 3412
83. H. Chakrapani, A.E. Maciag, M.L. Citro, L.K. Keefer, and J.E. Saavedra Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs Org. Lett 10 2008 5155 5158
84. D. Basudhar, G. Bharadwaj, R.Y. Cheng, S. Jain, S. Shi, and J.L. Heinecke Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives J. Med. Chem 56 2013 7804 7820
85. D. Andrei, A.E. Maciag, H. Chakrapani, M.L. Citro, L.K. Keefer, and J.E. Saavedra Aryl Bis(diazeniumdiolates): potent Inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities J. Med. Chem 51 2008 7944 7952
86. R.J. Holland, A.E. Maciag, V. Kumar, L. Shi, J.E. Saavedra, and R.K. Prud'homme Cross-linking protein glutathionylation mediated by O2-arylated bis-diazeniumdiolate "double JS-K" Chem. Res. Toxicol 25 2012 2670 2677
87. R.I. Bello, C. Gómez-Díaz, F. Navarro, F.J. Alcaín, and J.M. Villalba Expression of NAD(P)H:quinone oxidoreductase 1 in HeLa cells: role of hydrogen peroxide and growth phase J. Biol. Chem 276 2001 44379 44384
88. G.A. Choudry, P.A.H. Stewart, J.A. Double, M.R.L. Krul, B. Naylor, and G.M. Flannigan A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9 Br. J. Cancer 85 2001 1137 1146
89. S. Danson, T.H. Ward, J. Butler, and M. Ranson DT-diaphorase: a target for new anticancer drugs Cancer Treat. Rev 30 2004 437 449
90. U. Schumacher, E. Adam, U. Zangemeister-Wittkel, and R. Gossrau Histochemistry of therapeutically relevant enzymes in human tumours transplanted into severe combined immunodeficient (SCID) mice: nitric oxide synthase - associated diaphorase, β-D-glucuronidase and nonspecific alkaline phosphatase Acta Histochem 98 1996 381 387
91. M. Hernick, C. Flader, and R.F. Borch Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase J. Med. Chem 45 2002 3540 3548
92. B. Huang, A. Desai, S. Tang, T.P. Thomas, and J.R. Baker The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release Org. Lett 12 2010 1384 1387
93. M. Jaffar, S.A. Everett, M.A. Naylor, S.G. Moore, S. Ulhaq, and K.B. Patel Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones Bioorg. Med. Chem. Lett 9 1999 113 118
94. M.A. Naylor, M. Jaffar, J. Nolan, M.A. Stephens, S. Butler, and K.B. Patel 2-cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo J. Med. Chem 40 1997 2335 2346
95. D. Ross, H.D. Beall, D. Siegel, R.D. Traver, and D.L. Gustafson Enzymology of bioreductive drug activation Br. J. Cancer Suppl. 27 1996 S1 S8
96. Z. Zhang, K. Tanabe, H. Hatta, and S.-I. Nishimoto Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity Org. Biomol. Chem 3 2005 1905 1910
97. J.-C. Andrez Mitomycins syntheses: a recent update Beilstein J. Org. Chem 5 2009 33
98. K. Sharma, A. Iyer, K. Sengupta, and H. Chakrapani INDQ/NO, a bioreductively activated nitric oxide prodrug Org. Lett 15 2013 2636 2639
99. M.A. Colucci, G.D. Couch, and C.J. Moody Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential Org. Biomol. Chem 6 2008 637 656
100. J.S. Dickey, B.J. Baird, C.E. Redon, M.V. Sokolov, O.A. Sedelnikova, and W.M. Bonner Intercellular communication of cellular stress monitored by g-H2AX induction Carcinogenesis 30 2009 1686 1695
101. J.A. Bridgewater, C.J. Springer, R.J. Knox, N.P. Minton, N.P. Michael, and M.K. Collins Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 Eur. J. Cancer 31A 1995 2362 2370
102. G.M. Anlezark, R.G. Melton, R.F. Sherwood, B. Coles, F. Friedlos, and R.J. Knox The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT) Biochem. Pharmacol 44 1992 2289 2295
103. C. Asche, P. Dumy, D. Carrez, A. Croisy, and M. Demeunynck Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy Bioorg. Med. Chem. Lett 16 2006 1990 1994
104. M.P. Hay, G.J. Atwell, W.R. Wilson, S.M. Pullen, and W.A. Denny Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in Conjunction with E. coli NITROREDUCTASE J. Med. Chem 46 2003 2456 2466
105. L. Hu, X. Wu, J. Han, L. Chen, S.O. Vass, and P. Browne Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs Bioorg. Med. Chem. Lett 21 2011 3986 3991
106. K. Sharma, K. Sengupta, and H. Chakrapani Nitroreductase-activated nitric oxide (NO) prodrugs Bioorg. Med. Chem. Lett 23 2013 5964 5967
107. G. Dachs, M. Hunt, S. Syddall, D. Singleton, and A. Patterson Bystander or no bystander for gene directed enzyme prodrug therapy Molecules 14 2009 4517 4545
108. S.O. Vass, D. Jarrom, W.R. Wilson, E.I. Hyde, and P.F. Searle E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954 Br. J. Cancer 100 2009 1903 1911
109. J.I. Grove, P.F. Searle, S.J. Weedon, N.K. Green, I.A. McNeish, and D.J. Kerr Virus-directed enzyme prodrug therapy using CB1954 Anticancer Drug Des 14 1999 461 472
110. A.E. Maciag, R.J. Holland, Y. Kim, V. Kumari, C.E. Luthers, and W.S. Sehareen Nitric Oxide (NO) Releasing Poly ADP-ribose Polymerase 1 (PARP-1) Inhibitors Targeted to Glutathione S-Transferase P1-Overexpressing Cancer Cells J. Med. Chem 57 2014 2292 2302